Comprehensive Hypertension 2007
DOI: 10.1016/b978-0-323-03961-1.50098-2
|View full text |Cite
|
Sign up to set email alerts
|

World Health Organization/International Society of Hypertension (WHO/ISH): Hypertension Guidelines and Statements

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

3
219
0
6

Year Published

2007
2007
2023
2023

Publication Types

Select...
9

Relationship

0
9

Authors

Journals

citations
Cited by 168 publications
(228 citation statements)
references
References 79 publications
3
219
0
6
Order By: Relevance
“…Cardiovascular events and dyslipidaemia T Kushiro et al patients, along with strict control of individual risk factors. [14][15][16] The present study showed that the greater the increase in follow-up SBP or DBP, the higher the incidence of resulting cardiovascular events, in particular CVA/TIA and stroke, reconfirming the importance of BP control in patients with dyslipidaemia too. Also, assessment of BP status not only at baseline but also during the follow-up period is important partly because adherence to antihypertensive therapy in patients with dyslipidaemia is not as good as one might expect.…”
Section: Discussionsupporting
confidence: 74%
See 1 more Smart Citation
“…Cardiovascular events and dyslipidaemia T Kushiro et al patients, along with strict control of individual risk factors. [14][15][16] The present study showed that the greater the increase in follow-up SBP or DBP, the higher the incidence of resulting cardiovascular events, in particular CVA/TIA and stroke, reconfirming the importance of BP control in patients with dyslipidaemia too. Also, assessment of BP status not only at baseline but also during the follow-up period is important partly because adherence to antihypertensive therapy in patients with dyslipidaemia is not as good as one might expect.…”
Section: Discussionsupporting
confidence: 74%
“…[7][8][9] We previously reported that hypertension is a strong risk factor for coronary heart disease (CHD) 10 and stroke, 11 and that pravastatin is effective to prevent cardiovascular events in patients with hypertension in the MEGA Study. 12 Guidelines for the treatment of hypertension have been formulated by groups in various countries across the globe, and include the US Joint National Committee, 13 World Health Organization/International Society of Hypertension 2003, 14 European Society of Hypertension (ESH)-European Society of Cardiology (ESC) 2007 15 and Japanese Society of Hypertension (JSH) 2009. 16 These guidelines universally recommend a treatment plan based on evaluation of CVD risk factors.…”
Section: Introductionmentioning
confidence: 99%
“…-Hypertension: patients were considered as hypertensive if the systolic blood pressure was C140 mm Hg and/or diastolic blood pressure was C90 mm Hg [18] and/or currently used anti-hypertensive medications. -Hypercholesterolemia was defined as total cholesterol C5.0 mmol/l [19]; and/or current use of lipid-lowering medication.…”
Section: Definitions Of Ethnicity and Cardiovascular Risk Factorsmentioning
confidence: 99%
“…1,6 Yet, the scientific evidence has neglected the accumulation aspects of PA in the treatment of hypertension and prehypertension. 1,6,7 The American College of Sports Medicine Position Stand on exercise and hypertension stated that there is limited evidence regarding the accumulation of several short sessions of PA on BP reduction 6 . This limited scientific evidence led to our work in the accumulation of PA as a treatment for prehypertension.…”
Section: Introductionmentioning
confidence: 99%